A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angioedema

Trial Profile

A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angioedema

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2018

At a glance

  • Drugs BCX 7353 (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Acronyms APEX-2
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 15 Mar 2018 According to a BioCryst Pharmaceuticals media release, the company look forward to report top-line results from this trial in the first half of 2019.
    • 15 Mar 2018 According to a BioCryst Pharmaceuticals media release, the first patient from this trial has been dosed.
    • 15 Mar 2018 Status changed from planning to recruiting, according to a BioCryst Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top